Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010

Ann Clin Microbiol Antimicrob. 2012 Oct 22:11:29. doi: 10.1186/1476-0711-11-29.

Abstract

Background: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a global surveillance study of antimicrobial susceptibility. This study reports data from Gram-negative isolates collected from centers in Latin America between 2004 and 2010.

Methods: Consecutive bacterial isolates were tested at each center using broth microdilution methodology as described by the Clinical Laboratory Standards Institute (CLSI). Susceptibility was determined using the CLSI interpretive criteria. For tigecycline the US Federal Drug Administration (FDA) criteria were used.

Results: A total of 16 232 isolates were analyzed. Susceptibility to imipenem, meropenem, and tigecycline was >95% against both non-extended-spectrum β-lactamase (ESBL) and ESBL producing Escherichia coli. Susceptibility to amikacin was also >95% for non-ESBL E. coli. 24.3% of E. coli were ESBL producers, ranging from 11.2% (58/519) in Colombia to 40.3% (31/77) in Honduras. Greater than 90% of non-ESBL Klebsiella pneumoniae were susceptible to tigecycline, carbapenems and amikacin. 35.3% of K. pneumoniae were ESBL producers, ranging from 17.2% (36/209) in Venezuela to 73.3% (55/75) in Honduras, with only imipenem and tigecycline maintaining >90% susceptibility. Greater than 90% of Klebsiella oxytoca, Enterobacter spp., and Serratia marcescens were susceptible to amikacin, carbapenems and tigecycline. The highest rates of susceptibility against Acinetobacter baumannii were seen for minocycline (89.4%) and imipenem (62.5%), while 95.8% of the A. baumannii isolates displayed an MIC≤2 μg/mL for tigecycline.

Conclusions: In this study carbapenems and tigecycline remain active against Enterobacteriaceae and A. baumannii; however, there is cause for concern with carbapenem non-susceptible isolates reported in all countries included in this study.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter baumannii / drug effects
  • Acinetobacter baumannii / isolation & purification
  • Amikacin / pharmacology
  • Anti-Bacterial Agents / pharmacology*
  • Carbapenems / pharmacology
  • Drug Resistance, Multiple, Bacterial*
  • Enterobacter / drug effects
  • Enterobacter / isolation & purification
  • Escherichia coli / drug effects
  • Escherichia coli / isolation & purification
  • Escherichia coli / metabolism
  • Imipenem / pharmacology
  • Klebsiella oxytoca / drug effects
  • Klebsiella oxytoca / isolation & purification
  • Klebsiella pneumoniae / drug effects
  • Klebsiella pneumoniae / isolation & purification
  • Latin America
  • Meropenem
  • Microbial Sensitivity Tests
  • Minocycline / analogs & derivatives*
  • Minocycline / pharmacology
  • Serratia marcescens / drug effects
  • Serratia marcescens / isolation & purification
  • Thienamycins / pharmacology
  • Tigecycline
  • United States
  • United States Food and Drug Administration
  • beta-Lactamases / pharmacology

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Thienamycins
  • Tigecycline
  • Imipenem
  • Amikacin
  • beta-Lactamases
  • Meropenem
  • Minocycline